Brief: Allena Pharmaceuticals Doses First Subject In Phase 1 Clinical Trial Of Alln-346, In Development For The Treatment Of Hyperuricemia In Patients With Gout And Advanced Chronic Kidney Disease
08/09/2020 14:01
Sept 8 (Reuters) - Allena Pharmaceuticals Inc ALNA.O :
* ALLENA PHARMACEUTICALS DOSES FIRST SUBJECT IN PHASE 1
CLINICAL
TRIAL OF ALLN-346, IN DEVELOPMENT FOR THE TREATMENT OF
HYPERURICEMIA IN PATIENTS WITH GOUT AND ADVANCED CHRONIC KIDNEY
DISEASE
Source text for Eikon: ID:nGNX3hlP2m
Further company coverage: ALNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allena Pharmaceuticals
See all newsBrief: Allena Pharmaceuticals Inc - On September 6, Received Notice From Nasdaq That Its Shares Will Be Suspended At Open Of Business On September 8, 2022
U.S. STOCKS ON THE MOVE-Relmada, Entera Bio, Eli Lilly
U.S. STOCKS ON THE MOVE-ChannelAdvisor, HyreCar, ADT, miners
U.S. STOCKS ON THE MOVE-Timken, Bed Bath & Beyond, HyreCar, chip stocks
Allena down on bankruptcy filing